Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns Click here to read the press release

Vericel manufactures advanced cell therapies for the sports medicine and severe burn care markets. The goal of our therapies is to repair or restore a patient’s damaged tissues or organs using their own cells. Please use the links to the right to visit our product websites.

NASDAQ: VCEL

$15.68 -0.1 (-0.63%)
Day High: $15.99
Day Low: $15.64
Volume: 159672
11:39 AM on
May 22, 2019
Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation